个人简介
现为北京市“创新团队”—抗病毒药物研发创新团队的主要成员之一，抗病毒药物北京市国际科技合作基地主要成员之一。主持过国家自然科学基金项目和北京市自然科学基金项目，参加科技部的重大科学研究计划（973）项目、国际合作项目（中意）、国家自然科学基金、北京市教委重大项目、北京市自然科学基金等科研项目。从2001年开始一直从事艾滋病病毒抑制剂的设计及机理研究，其中发现了一个活性非常好的多肽融合抑制剂。现主要从事抗艾滋病药物的设计、合成、抑制剂的定量构效关系、计算机模拟、结合动力学等方面的研究。在各级、各类刊物中发表学术论文六十余篇，其中SCI 收录24篇。Current Pharmaceutical Design (SCI二区) 客座编辑；Journal of clinical research in HIV AIDS and prevention荣誉编委；Symbiosis Journal of Virology & Retrovirology编委；计算生物学杂志编委。Current Pharmaceutical Design，Plos One等杂志审稿人。
近期论文
查看导师最新文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
[1]Tan J*, Su M, Zeng Y, Wang C: Design, synthesis and activity evaluation of novel peptide fusion inhibitors targeting HIV-1 gp41. Bioorg Med Chem 2016, 24(2):201-206.
[2]Su M, Tan J*, Lin CY: Development of HIV-1 integrase inhibitors: recent molecular modeling perspectives. Drug Discov Today 2015, 20(11):1337-1348.
[3]Xie XL, Li CH, Yang YX, Jin L, Tan JJ, Zhang XY, Su JG, Wang CX: Allosteric transitions of ATP-binding cassette transporter MsbA studied by the adaptive anisotropic network model. Proteins 2015, 83(9):1643-1653.
[4]Zhang XY, Deng DJ, Tan JJ, et al., Pharmacophore and Docking-based 3D-QSAR Studies on HIV-1 Integrase Inhibitors, Chem Res Chin Univ, 2014, 30(2): 297-305.
[5]Zhang HGC, Li CH, Yang F, et al., Cation-pi Interactions at Non-redundant Protein-RNA Interfaces, Biochemistry-Moscow, 2014, 79(7): 643-652.
[6]Ma X, Tan J, Su M, et al., Molecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanism, PLoS One, 2014, 9(11): e111923.
[7]Liu W, Tan JJ, Mehryar MM, et al., Peptide HIV fusion inhibitors: modifications and conjugations, Medchemcomm, 2014, 5(10): 1472-1482.
[8]Li S, Liu B, Li CH, et al., E92A Is an Activity Recovery Mutation of HIV-1 Integrase Drug Resistance Mutation N155S, Prog Biochem Biophys, 2014, 41(5): 472-479.
[9]Li CH, Yang YX, Su JG, et al., Allosteric Transitions of the Maltose Transporter Studied by an Elastic Network Model, Biopolymers, 2014, 101(7): 758-768.
[10]Xu XJ, Su JG, Liu B, Li CH, Tan JJ, Zhang XY, Chen WZ, Wang CX. Reverse Virtual Screening on Persistent Organic Pollutants 4,4 '-DDE and CB-153. Acta Physico-Chimica Sinica, 2013, 29(10): 2276-2285
[11]谭建军, 王遥, 王存新. 抗HIV融合抑制剂的定量构效关系. 北京工业大学学报, 2013, 39(2): 309-313.
[12]刘昕, 谭建军, 陈慰祖, 刘斌, 李杉, 王存新. 用支持向量机预测HIV－1 整合酶抑制剂活性. 北京工业大学学报, 2013, 2013(39): 634-640.
[13]Tan JJ, Wang CX. The Development of Novel Inhibitors for the Treatment of HIV Infection. Curr Pharm Des, 2013, 19(10): 1765-1766.
[14]Tan JJ, Ma XT, Liu C, Zhang XY, Wang CX. The Current Status and Challenges in the Development of Fusion Inhibitors as Therapeutics for HIV-1 Infection. Curr Pharm Des, 2013, 19(10): 1810-1817.
[15]Xu XJ, Su JG, Liu B, Li CH, Tan JJ, Zhang XY, Chen WZ, Wang CX. Reverse Virtual Screening on Persistent Organic Pollutants 4,4 '-DDE and CB-153. Acta Physico-Chimica Sinica, 2013, 29(10): 2276-2285.
[16]Tan JJ, Liu C, Sun XH, Cong XJ, Hu LM, Wang CX, Liang XJ. Perspectives on Developing Small Molecule Inhibitors Targeting HIV-1 Integrase. Mini-Rev Med Chem, 2012, 12(9):875-89.
[17]Tan JJ, Zhang B, Cong XJ, Yang LF, Liu B, Kong R, Kui ZY, Wang CX, Hu LM. Computer-Aided Design, Synthesis, and Biological Activity Evaluation of Potent Fusion Inhibitors Targeting HIV-1 gp41. Med Chem, 2011, 7(4):309-16.（并列第一作者）
[18]Li P, Liu M, Tan JJ, Zhang XY, Chen WZ, Wang CX. Insight into the Inhibitory Mechanism and Binding Mode Between D77 and HIV-1 Integrase by Molecular Modeling Methods Journal of Biomolcular Structure and Dynamics, 2011, 29(2):251-423.（并列第一作者）
[19]Tan JJ, Cong XJ, Hu LM, Wang CX, Jia L, Liang XJ. Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection. Drug Discov Today, 2010, 15(5-6):186-97.（并列第一作者）
[20]Luo ZG, Tan JJ, Zeng Y, Wang CX, Hu LM. Development of Integrase Inhibitors of Quinolone Acid Derivatives for Treatment of AIDS: An Overview. Mini-Rev Med Chem, 2010, 10(11):1046-57.（并列第一作者）
京公网安备 11010802027423号